Status:
COMPLETED
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma
Lead Sponsor:
AstraZeneca
Conditions:
Recurrent Glioblastoma
Eligibility:
All Genders
18-100 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemoth...
Eligibility Criteria
Inclusion
- Confirmation of recurrent glioblastoma
- Life expectancy ≥ 12 weeks
- Received only one prior systemic chemotherapy regimen and this regimen must contain temozolomide
Exclusion
- Patients on enzyme-inducing anti-epileptic drugs within 3 weeks prior to randomisation
- Poorly controlled hypertension
- Previous anti-angiogenesis (eg bevacizumab, sorafenib, sunitinib) therapy
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
423 Patients enrolled
Trial Details
Trial ID
NCT00777153
Start Date
October 1 2008
End Date
September 1 2016
Last Update
December 28 2016
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Pheonix, Arizona, United States
3
Research Site
Los Angeles, California, United States
4
Research Site
New Haven, Connecticut, United States